The United States has postponed the implementation of a 50% additional tariff on Canadian alcohol, dairy products, and automobiles to 1:01 PM Korean time on the 22nd. This measure is a temporary delay rather than a withdrawal of tariffs, and U.S.-Canada trade negotiations will continue until the new implementation date. The White House announced on the 18th that it would change the effective date of three additional tariff measures announced on July 20. President Donald Trump indicated that the 50% additional tariff was in response to Canada’s discriminatory restrictions on U.S. products. The White House explained that the negotiation situation was cited as the reason for the delay, noting that Canada had shown willingness to eliminate discriminatory measures. The U.S. stated that Canadian imports of U.S. alcohol decreased by approximately 81% from March 2025 to February 2026. Canada imposes a 25% tariff on certain U.S. vehicles, and while most existing retaliatory tariffs have been lifted, tariffs on steel, aluminum, and automobiles remain in place. This delay does not signify the end of trade conflicts, and the remaining procedures involve the enforcement notice from the U.S. Customs and Border Protection and potential modifications to the tariff schedule. Any further extensions or separate agreements would require an official announcement from the White House or the Canadian government.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.












Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.


